JP2014518898A5 - - Google Patents

Download PDF

Info

Publication number
JP2014518898A5
JP2014518898A5 JP2014514452A JP2014514452A JP2014518898A5 JP 2014518898 A5 JP2014518898 A5 JP 2014518898A5 JP 2014514452 A JP2014514452 A JP 2014514452A JP 2014514452 A JP2014514452 A JP 2014514452A JP 2014518898 A5 JP2014518898 A5 JP 2014518898A5
Authority
JP
Japan
Prior art keywords
mcam
antigen
binds
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014514452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518898A (ja
JP6305919B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/000274 external-priority patent/WO2012170071A1/en
Publication of JP2014518898A publication Critical patent/JP2014518898A/ja
Publication of JP2014518898A5 publication Critical patent/JP2014518898A5/ja
Application granted granted Critical
Publication of JP6305919B2 publication Critical patent/JP6305919B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014514452A 2011-06-06 2012-06-06 Mcamアンタゴニスト及び治療の方法 Expired - Fee Related JP6305919B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161493780P 2011-06-06 2011-06-06
US61/493,780 2011-06-06
US201161527481P 2011-08-25 2011-08-25
US61/527,481 2011-08-25
PCT/US2012/000274 WO2012170071A1 (en) 2011-06-06 2012-06-06 Mcam antagonists and methods of treatment

Publications (3)

Publication Number Publication Date
JP2014518898A JP2014518898A (ja) 2014-08-07
JP2014518898A5 true JP2014518898A5 (enExample) 2015-07-30
JP6305919B2 JP6305919B2 (ja) 2018-04-04

Family

ID=46354461

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014514452A Expired - Fee Related JP6305919B2 (ja) 2011-06-06 2012-06-06 Mcamアンタゴニスト及び治療の方法

Country Status (6)

Country Link
US (2) US20140314744A1 (enExample)
EP (1) EP2718327A1 (enExample)
JP (1) JP6305919B2 (enExample)
CA (1) CA2836373A1 (enExample)
HK (1) HK1197072A1 (enExample)
WO (1) WO2012170071A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009212789B2 (en) * 2009-06-09 2014-05-15 Val-Chum, Limited Partnership Ninjurin-1 and/or MCAM Modulation and Uses Thereof
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗mcam抗體及相關使用方法
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
EP3116906A1 (en) 2014-03-12 2017-01-18 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法
WO2015136472A1 (en) * 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
US20170002077A1 (en) 2014-03-13 2017-01-05 Prothena Biosciences Limited Combination treatment for multiple sclerosis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
EP4602174A1 (en) 2022-10-13 2025-08-20 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
CN117491647A (zh) * 2023-11-14 2024-02-02 惠州市振原科技有限公司 帕金森病患者外周血标记物及其应用
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5224539A (en) 1991-06-14 1993-07-06 Coen Company, Inc. Cooling system for air heaters and the like
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
GB9406974D0 (en) 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
CA2441953A1 (en) * 2001-03-23 2002-10-03 The Board Of Regents Of The University Of Texas System Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors
TWI327597B (en) * 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
JP2005514409A (ja) * 2001-12-28 2005-05-19 アブジェニックス・インコーポレーテッド Muc18抗原に対する抗体の使用
EP1467756A4 (en) 2001-12-28 2007-03-21 Abgenix Inc METHODS OF USING ANTI-MUC18 ANTIBODIES
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
CN101245101B (zh) * 2008-01-31 2013-10-16 中国科学院生物物理研究所 抗人cd146的单克隆抗体,包含其的组合物,检测可溶性cd146的方法
US8293468B2 (en) * 2009-06-10 2012-10-23 Centre Hospitalier De L'université De Montréal MCAM modulation and uses thereof

Similar Documents

Publication Publication Date Title
RU2018132044A (ru) Антитела против тау
WO2015091853A3 (en) Human anti-cd40 human antibodies
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
IL267382A (en) Oncostatin m receptor antigen binding proteins
IL229618B (en) Isolated antibody that binds fcrn
EP3004168A4 (en) Chimeric antigen receptor-targeting monoclonal antibodies
PH12015501505B1 (en) Antibodies that bind to tl1a and their uses
WO2014189973A3 (en) Anti-transferrin receptor antibodies and methods of use
PT2977385T (pt) Anticorpos humanizados, específicos da forma protofibrilar do peptídeo beta-amiloide
JP2013539454A5 (enExample)
IL221408B (en) Monoclonal antibodies against c-met
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
EA202091315A2 (ru) Антитела человека, связывающиеся с g-белком rsv
PT3016681T (pt) Anticorpos humanizados ou quiméricos cd3
EP2771031A4 (en) ALPHA SYNNUCLEIN DETECTING HUMANIZED ANTIBODIES
CL2014000574A1 (es) Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
UA111818C2 (uk) Антитіло проти csf-1r
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
CA2872308A1 (en) Novel ha binding agents
EA201291065A1 (ru) Антитела против vla-4
IL236549A0 (en) Antibodies to a beta c-terminal or central epitope and uses thereof
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
IL258914A (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
EP2949750A4 (en) ANTIBODY-BINDING PEPTIDE
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител